CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc.

1:17-cv-00389

Overview

Case Number 1:17-cv-00389
Filing Date 2017-04-07
Status Terminated
Termination Date 2019-01-02
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

8 Attorneys Listed

James Michael Lennon

Devlin Law Firm

Tel: +1 (302) 449-9010
Fax: +1 (302) 353-4251

1526 Gilpin Avenue, 19806

Shannon M. Bloodworth

Email: SBloodworth@perkinscoie.com

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Maria A. Stubbings

Email: MStubbings@perkinscoie.com

David L. Anstaett

Email: danstaett@perkinscoie.com

Danielle S. Grant-Keane

Email: dgrantkeane@perkinscoie.com

Bryan D. Beel

Email: bbeel@perkinscoie.com

Brandon M. White

Email: BMWhite@perkinscoie.com

Plaintiff

Novartis AG Operating Company

Represented By

7 Attorneys Listed

Christina Schwarz

Email: cschwarz@venable.com

Susanne L. Flanders

Email: sflanders@venable.com

Shannon K. Clark

Email: sclark@venable.com

Nicholas N. Kallas

Email: nkallas@venable.com

Laura K. Fishwick

Email: lfishwick@venable.com

Christopher E. Loh

Email: cloh@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

7 Attorneys Listed

Susanne L. Flanders

Email: sflanders@venable.com

Shannon K. Clark

Email: sclark@venable.com

Nicholas N. Kallas

Email: nkallas@venable.com

Laura K. Fishwick

Email: lfishwick@venable.com

Jared L. Stringham

Email: jlstringham@venable.com

Christopher E. Loh

Email: cloh@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 3 proceedings
🏛️
USPTO PTAB Trials 6 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (9 found):
PTAB: 6 U.S. Courts: 3
USPTO PTAB Trial 2016-05-26
IPR2016-01103

Breckenridge Pharmaceutical, Inc. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Institution Denied
USPTO PTAB Trial 2016-05-26
IPR2016-01102

Roxane Laboratories, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2016-05-17
IPR2016-01059

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Institution Denied
USPTO PTAB Trial 2016-05-10
IPR2016-01023

BRECKENRIDGE PHARMACEUTICAL, INC. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2015-10-26
IPR2016-00084

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2015-10-26
IPR2016-00075

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (7297703)
Status: Institution Denied
U.S. District Court 2016-06-13
1:16-cv-00431

Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.

U.S. Family Sibling (["US5665772", "US8410131", "US8778962", "US7297703", "US7741338", "US6239124", "US6455518"])
Status: DED
U.S. District Court 2014-10-10
1:14-cv-01289

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.

U.S. Family Sibling (["US5665772", "US6004973", "US6455518", "US6239124"])
Status: DED
U.S. District Court 2014-08-13
1:14-cv-01043

Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.

U.S. Family Sibling (["US5665772", "US6004973", "US6239124", "US6455518"])
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5665772
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Filed: 1993-09-24
Issued: 1997-09-09
Expired (Term Ended) +2176d PTA
Expires: 2019-09-09
US8778962
Treatment of solid tumors with rapamycin derivatives
Filed: 2012-07-11
Issued: 2014-07-15
Active (5.6 yrs remaining)
Expires: 2032-07-11
US8617598
Pharmaceutical compositions comprising colloidal silicon dioxide
Filed: 2012-06-05
Issued: 2013-12-31
Active (5.5 yrs remaining)
Expires: 2032-06-05
US7297703
Macrolides
Filed: 2004-12-23
Issued: 2007-11-20
Expired (Term Ended)
Expires: 2024-12-23

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+2176 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

20

Dispositive

0

Granted

0

Denied

0

Pending / Review

20

Motions by Category

Claim Construction / Markman Filing 18 Procedural / Extension Motion 2

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
CLAIM CONSTRUCTION ORDER. Signed by Judge Richard G. Andrews on 7/6/2018. (nms) (Entered: 07/06/2018)
Entry #74 • 2018-07-06 Document →
Claim Construction / Markman Filing Pending / Under Review
PROPOSED Claim Construction Order, by Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/6/2018 (nms). (Entered: 07/05/2018)
Entry #73 • 2018-07-05 Document →
Claim Construction / Markman Filing Pending / Under Review
MEMORANDUM OPINION providing claim construction for multiple terms in U.S. Patent Nos. 8,778,962, 8,617,598, and 7,297,703. Within five days the parties shall...
Entry #72 • 2018-06-29 Document →
Claim Construction / Markman Filing Pending / Under Review
SEALED Official Transcript of Markman Hearing held on 06-14-18 before Judge Richard G. Andrews. Court Reporter/Transcriber Stacy Ingram. (lad) Modified on 7/24/...
Entry #71 • 2018-06-28 Document →
Claim Construction / Markman Filing Pending / Under Review
Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Claim Construction. (Silver, Daniel) (Entered: 06/14/2018)
Entry #68 • 2018-06-14 Document →
Claim Construction / Markman Filing Pending / Under Review
[SEALED] Letter to Honorable Richard G. Andrews from James M. Lennon regarding Markman Hearing Confidentiality issues. (Lennon, James) (Entered: 06/13/2018)
Entry #67 • 2018-06-13 Document →

Docket Entries

(80 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2117758.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A,B, and C.)(crb) (Additional attachment(s) added on 4/7/2017: # 2 Civil Cover Sheet) (crb). (Entered: 04/07/2017)

Entry #1 • 2017-04-07
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (crb) (Entered: 04/07/2017)

Entry #2 • 2017-04-07
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,665,772; 8,778,962; 8,617,598. (crb) (Entered: 04/07/2017)

Entry #3 • 2017-04-07
1

Disclosure Statement pursuant to Rule 7.1: Identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (crb) (Entered: 04/07/2017)

Entry #4 • 2017-04-07
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Novartis AG. (crb) (Entered: 04/07/2017)

Entry #5 • 2017-04-07
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc